摘要
目的:通过临床病例的研究,检测CysLT1R和CysLT2R在乳腺癌中的表达情况,并分析C2ysLT1R和CysLT2R与乳腺癌患者病理特征及预后的关系。方法:采用实时荧光定量PCR方法,从mRNA水平上检测90例原发乳腺癌组织和30例匹配的癌旁组织中CysLT1R和CysLT2R基因的表达量,分析二者与临床病理学参数之间的关系,以及与乳腺癌患者预后的关系。结果:乳腺癌组织CysLT1R基因的表达明显高于癌旁组织,乳腺癌组织CysLT2R基因的表达明显低于癌旁组织,两者差异具有统计学意义(P<0.01)。乳腺癌组织中CysLT1R的表达程度与肿瘤大小、组织学类型、淋巴结转移、TNM分期的表达呈正相关(P<0.05),CysLT2R的表达程度与肿瘤大小、组织学类型、淋巴结转移的表达呈负相关(P<0.05)。Kaplan-Meier生存分析结果显示,CysLT1R mRNA高表达者的总的5年生存率显著低于低表达水平者(P=0.035),CysLT2R mRNA高表达者的总的5年生存率显著高于低表达水平者(P=0.025)。结论:CysLT1R和CysLT2R可作为乳腺癌判断预后的分子标志物。
Objective： This study aimed to investigate the expression of CysLT1R and CysLT2R mRNA in breast cancer tissues, and to explore its relationship with clinicopathological features and prognosis. Methods： Breast cancer and normal para-neoplastic tissues were obtained from 90 and 30 patients, respectively. The expression of CysLT1R and CysLT2R mRNA was determined by real-time polymerase chain reaction. The relationships of this expression with clinicopathological features and prognosis were analyzed. Results： CysLT 1R gene expression was significantly higher in breast cancer tissues than in para-neoplastic tissues. CysLT2R gene expression was significantly lower in breast cancer tissues than in the adjacent non-cancerous tissues （P〈0.01）. The tumor size, histological type, lymph node metastasis, and TNM staging expression were positively correlated with the CysLT1R expression in breast cancer （P〈0.05）. However, these clinical factors were negatively correlated with CysLT2R expression （P〈0.05）. Kaplan - Meier survival analysis showed that patients with elevated CysLT1R expression in breast cancer exhibited poor prognosis （P〈0.05）, whereas patients with elevated CysLT2R expression in breast cancer showed good prognosis （P〈0.05）. Conclusion： CysLT1R and CysLT2R may be new molecular markers for the prognosis of breast cancer patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第20期1522-1526,共5页
Chinese Journal of Clinical Oncology
基金
天津市高等学校科技发展基金计划项目(编号:20090139)
天津市应用与基础及前沿技术研究计划重点项目(编号:08JCZD-JC25100)
教育部留学回国人员科研启动基金(编号:2009J1590)资助~~
